US FDA probes cardio events, deaths in Sanofi halted Multaq study
This article was originally published in Scrip
Two weeks after Sanofi halted a Phase IIIb study of its antiarrhythmic drug Multaq (dronedarone) in patients with permanent atrial fibrillation at the behest of the trial's data monitoring committee after a two-fold increase in death, stroke and heart failure-related hospitalizations were identified, the US FDA said it was taking up an examination of the data (scripintelligence, 8 July 2011).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.